Breakthrough bleeding and spotting is disruptive to your patients...
and your practice

In clinical studies, bleeding irregularities were

  • the #1 reason women stopped taking the Pill1 and
  • the reason for 30% of calls to a medical office regarding OC-related side effects2
When it comes to breakthrough bleeding and spotting, not all OCs are alike

ORTHO TRI-CYCLEN® LO demonstrated a favorable bleeding profile. Click on the following links to learn more about head-to-head trials vs YAZ®3
and vs Loestrin® Fe*4


ORTHO TRI-CYCLEN® LO is a combination OC comprised of 25 mcg ethinyl estradiol and norgestimate, a unique progestin. Norgestimate is highly selective and efficient, allowing for high progestational activity with low androgenic activity often associated with acne/oily skin, hirsutism, and weight gain.5,6 The combination of a low dose of norgestimate and a lower level of estrogen allows for highly effective contraception and favorable cycle control. ORTHO TRI-CYCLEN® LO demonstrates low rates of unexpected bleeding and spotting and provides predictable periods, regardless of weight, while offering an excellent tolerability profile.4

In a clinical trial, the most frequently reported adverse events in the ORTHO TRI-CYCLEN® LO treatment group were headache, upper respiratory tract infection, nausea, abdominal pain, breast pain, dysmenorrhea, and sinusitis. The discontinuation rate due to adverse events was 4%.

*Loestrin® Fe 1/20.
Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets) is a registered trademark of Warner Chilcott.
YAZ (drospirenone/ethinyl estradiol) is a registered trademark of Bayer HealthCare Pharmaceuticals, Inc.

    References:
  1. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol. 1998;179:577-582.
  2. Rosenberg MJ, Waugh MS, Burnhill MS. Compliance, counseling and satisfaction with oral contraceptives: a prospective e valuation. Fam Plann Perspect. 1998;30(2):89-92, 104.
  3. Kaunitz AM, Burkman RT, Fisher AC, LaGuardia KD. Cycle control with a 21-day compared with a 24-day oral contraceptive pill: a randomized controlled trial. Obstet Gynecol. 2009;114:1205-1212.
  4. Hampton RM, Short M, Bieber E, et al. Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20. Contraception. 2001;63:289-295.
  5. Phillips A, Hahn DW, McGuire JL. Preclinical evaluation of norgestimate, a progestin with minimal androgenic activity. Am J Obstet Gynecol. 1992;167:1191-1196.
  6. Dickey RP. Managing Contraceptive Pill Patients. 12th ed. New Orleans, LA: Emis Medical Publishers; 2004.